Chiara Caparello

Pisa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Journal: Cancers

Published: December 21, 2025

Mixed endometrial carcinoma: is it time to profile the two components separately?

Mixed endometrial carcinoma: is it time to profile the two components separately?

Journal: Frontiers in oncology

Published: October 30, 2025

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Journal: Oncology research

Published: September 25, 2025

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.

Journal: Anti-cancer agents in medicinal chemistry

Published: November 16, 2020

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.

Journal: Annals of surgery

Published: November 06, 2018

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Journal: Tumori

Published: May 10, 2018

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

Journal: Cancer biomarkers : section A of Disease markers

Published: December 28, 2017

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

Journal: British journal of cancer

Published: December 18, 2017

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Journal: Journal of hepatology

Published: December 01, 2017

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

Journal: Scientific reports

Published: April 04, 2017

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Journal: OncoTargets and therapy

Published: October 28, 2016

Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.

Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.

Journal: British journal of cancer

Published: April 29, 2016

Showing 1-12 of 25

Last Updated: 09/26/2026